Your browser doesn't support javascript.
loading
The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham, James; Valenti, Melanie R; De-Haven-Brandon, Alexis K; Vidot, Susanne; Eccles, Suzanne A; Kaye, Stan B; Richardson, Alan.
Afiliação
  • Witham J; Section of Medicine, The Institute of Cancer Research, Sutton, United Kingdom.
Clin Cancer Res ; 13(23): 7191-8, 2007 Dec 01.
Article em En | MEDLINE | ID: mdl-18056200
ABSTRACT

PURPOSE:

The effective treatment of ovarian cancer is hampered by the development of drug resistance, which may be mediated by members of the Bcl-2 family of apoptosis regulators. ABT-737 is a recently described inhibitor of members of this family. We investigated whether this compound could sensitize ovarian cancer cells to chemotherapeutic agents. EXPERIMENTAL

DESIGN:

The sensitivity of ovarian cancer cell lines to ABT-737 in combination with either carboplatin or paclitaxel was tested either in vitro by assessing cell growth/survival and apoptosis or in xenograft studies.

RESULTS:

As a single agent, ABT-737 inhibited the growth of eight ovarian cancer cell lines, although with relatively poor potency. However, ABT-737, but not a less active enantiomer, increased the sensitivity of several cell lines to carboplatin. The increased sensitivity to carboplatin was accompanied by a decrease in time at which apoptosis was observed when assessed according to the number of attached cells, PARP cleavage, and nucleosome formation. ABT-737 was more effective at sensitizing IGROV-1 cells when ABT-737 was administered after carboplatin. In addition, ABT-737 significantly enhanced the activity of carboplatin in one of three primary cultures derived directly from ascitic tumor cells in patients recently treated with chemotherapy. Small interfering RNA directed to Bcl-X(L) also increased the sensitivity of ovarian cancer cell lines to carboplatin. ABT-737 was also able to augment the inhibition of IGROV-1 tumor xenograft growth beyond that obtained with carboplatin alone.

CONCLUSIONS:

These data suggest that ABT-737, in combination with carboplatin, may find utility in the treatment of patients with ovarian cancer.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Sulfonamidas / Compostos de Bifenilo / Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatina / Paclitaxel / Proteínas Proto-Oncogênicas c-bcl-2 / Proteína bcl-X / Nitrofenóis Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2007 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Sulfonamidas / Compostos de Bifenilo / Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatina / Paclitaxel / Proteínas Proto-Oncogênicas c-bcl-2 / Proteína bcl-X / Nitrofenóis Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2007 Tipo de documento: Article